Early Results

Showing 1482 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

Cavco Industries Posts Strong Q1 2026 Results on Surging Demand and Strategic Execution

Cavco Industries (CVCO) reported robust first-quarter fiscal 2026 earnings, with revenue climbing 9.5% year-over-year and operating profit jumping approximately 50%. The manufactured housing leader credited strategic production increases, improved pricing, and a rebound in its financial services segment for the strong performance, while also highlighting its pending acquisition of American Homestar.